查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1943414

Montelukast sodium市場依劑型、劑量、用途及通路分類，全球預測（2026-2032）

Montelukast Sodium Market by Formulation, Dosage Strength, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年Montelukast sodium市場價值為 4.5912 億美元，預計到 2026 年將成長至 4.9096 億美元，預計到 2032 年將達到 7.4037 億美元，複合年成長率為 7.06%。

關鍵市場統計數據
基準年 2025 4.5912億美元
預計年份：2026年 4.9096億美元
預測年份 2032 7.4037億美元
複合年成長率 (%) 7.06%

Montelukast sodium的策略性應用：面向知情決策者的臨床效用、法規環境和以病人為中心的意義框架

Montelukast sodium是一種口服白三烯受體拮抗劑，在呼吸系統和過敏性疾病的治療中佔據著獨特的地位，並擁有悠久的臨床效用歷史。其治療範圍涵蓋兒童到成人，能夠有效抑制氣喘和過敏性鼻炎相關的發炎通路，同時每日一次的給藥方案也滿足了患者的依從性需求。臨床醫生高度重視其便利性、良好的耐受性以及在特定患者群體中作為單藥治療和輔助性治療的效用，這些臨床特性持續影響著不同醫療機構的治療流程。

臨床證據、監管審查和分銷動態方面的變革性發展正在重塑Montelukast sodium的競爭格局和業務運營。

Montelukast sodium的市場格局正受到科學、監管和商業性因素的多重影響而重塑，相關人員的期望和營運重點也隨之改變。藥物警戒技術的進步和大規模真實世界證據的積累，使得安全訊號受到更嚴格的審查，並促使處方醫生和患者之間進行更深入的風險獲益討論。同時，生物目標和先進吸入控制藥物的出現，正在改變治療格局，重塑特異性通路治療方案，並引發關於現有口服藥物重新定位的討論。

美國關稅調整至2025年如何引發策略採購變化與供應鏈調整，進而影響Montelukast sodium的取得與分銷動態？

國際貿易和海關制度的政策趨勢，特別是美國在2025年前實施的措施，正對原料原料藥和製劑的供應鏈成本、籌資策略和採購決策產生重大影響。關稅差異和日益複雜的進口合規流程迫使製造商和經銷商重新評估製造地、供應商冗餘和海關最佳化策略。這些調整並非只是貿易問題；它們還會影響整個供應商網路的庫存管理實務、前置作業時間緩衝和合約條款。

透過對製劑形式、劑量強度、臨床用途和分銷管道進行詳細的細分分析，制定產品定位、生產製造和通路拓展策略。

強大的細分分析揭示了Montelukast sodium在製劑形式、劑量強度、給藥方法和分銷管道等方面的不同臨床、商業性和營運影響。就製劑形式而言，咀嚼錠、口服顆粒劑和一般錠劑在患者遵從性和生產方面各有不同。咀嚼片和口服顆粒劑尤其適用於兒童患者群體，需要專門的策略來確保其穩定性和偏好，而普通片劑則更注重成本效益和已確立的成人劑量。在這些劑型之間轉換時，需要仔細選擇輔料、包裝設計以及與患者溝通，以維持治療效果。

美洲、歐洲、中東和非洲以及亞太地區特有的臨床、監管和分銷趨勢正在影響藥物准入和商業化策略。

在美洲、歐洲、中東和非洲以及亞太地區，區域差異對Montelukast sodium的臨床實踐模式、監管預期和分銷模式的形成起著至關重要的作用。在美洲，醫療保健系統支付方趨勢各異，且都注重成本效益和病患依從性。在都市區和綜合醫療網路中，處方集管理和基於價值的合約受到重視，而社區藥房仍然是門診病人獲取藥物的核心管道。監管機構和專業協會會影響附加檔的內容和安全建議，進而影響處方醫師的信心和病人的接受度。

製造商、契約製造製造商、經銷商和數位健康合作夥伴如何影響Montelukast sodium的生產可靠性、分銷管道的履行以及臨床應用。

製造商、合約研究組織、專科經銷商和藥房網路之間的競爭與合作動態影響著Montelukast sodium的生產、供應和市場定位。擁有現有藥品組合的成熟製藥公司透過整合通路策略來推廣該產品，優先發展藥物監測基礎設施並建立與臨床醫生的長期合作關係。他們的投資往往集中在標籤管理、兒童製劑支援以及廣泛的教育和宣傳活動上，以維持處方醫生和患者的信任。

為生產商和通路合作夥伴提供優先的實用建議，以加強藥物警戒、提高供應鏈韌性並推動以患者為中心的Montelukast sodium商業化。

藥物研發、分銷和臨床倡導領域的領導者應採取多管齊下的策略，使產品管理與現代供應鏈的實際情況和不斷變化的臨床預期相契合。首先，應投資健全的藥物監測計畫和透明的安全溝通，以維持處方醫師的信心並支持合理的治療用藥。這些努力應與臨床醫生教育相結合，闡明Montelukast在目前治療流程中的作用，並確定可能受益的患者群體。

本文描述了用於得出有關Montelukast sodium的臨床和操作性可操作結論的證據來源、專家諮詢和分析方法。

本分析所依據的研究綜合了多方面的證據，以確保觀點平衡且切實可行。主要資訊來源包括對臨床專家、藥屋主任和供應鏈經理的訪談，以了解醫療專業人員的觀點和營運限制。二級資訊來源包括監管指導文件、同行評審的臨床文獻和政策聲明，以深入了解安全性、治療定位和區域監管趨勢。此外，還查閱了貿易和海關出版物，以了解與供應鏈規劃相關的關稅和採購考量。

總結性分析強調了協作式藥物監測、供應鏈靈活性以及基於證據的商業策略對於Montelukast sodium的重要性。

總之，儘管Montelukast sodium在呼吸系統和過敏性疾病的治療中仍具有臨床價值，但其持續效用取決於嚴密的安全管理、靈活的供應策略和精準的臨床定位。不斷變化的藥物警戒預期、治療方案的更新換代以及分銷管道的創新，都要求相關人員積極主動地收集證據、最佳化通路並與監管機構保持溝通。那些能夠將臨床訊息與營運韌性相結合，並投資於有針對性的真實世界研究的機構，將更有能力有效地支持臨床醫生和患者。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章Montelukast sodium市場以劑型分類

  • 咀嚼片
  • 口服顆粒劑
  • 藥片

第9章Montelukast sodium市場：依劑量分類

  • 10mg
  • 4mg
  • 5mg

第10章Montelukast sodium市場：依應用領域分類

  • 過敏性鼻炎
  • 氣喘
  • 運動誘發支氣管收縮

第11章Montelukast sodium市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章Montelukast sodium市場區域概覽

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章Montelukast sodium市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國Montelukast sodium市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國：Montelukast sodium市場

16. 中國：Montelukast sodium市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alembic Pharmaceuticals Limited
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Drugs Limited
  • Jubilant Generics Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Cadila
Product Code: MRR-F847BD9C7293

The Montelukast Sodium Market was valued at USD 459.12 million in 2025 and is projected to grow to USD 490.96 million in 2026, with a CAGR of 7.06%, reaching USD 740.37 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 459.12 million
Estimated Year [2026] USD 490.96 million
Forecast Year [2032] USD 740.37 million
CAGR (%) 7.06%

A strategic introduction to montelukast sodium that frames clinical utility, regulatory context, and patient-centered implications for informed decision-makers

Montelukast sodium occupies a distinct position in respiratory and allergic disease management as an oral leukotriene receptor antagonist with long-standing clinical utility. Its role spans pediatric and adult therapeutic paradigms, offering once-daily dosing that aligns with adherence needs while addressing inflammatory pathways implicated in asthma and allergic rhinitis. Clinicians value its convenience, tolerability profile, and utility as both monotherapy and adjunctive therapy in specific patient cohorts, and these clinical characteristics continue to shape treatment algorithms across care settings.

From a regulatory perspective, montelukast has traversed decades of post-market surveillance and label refinements, prompting careful risk-benefit assessments that influence prescriber behavior and patient counseling. Concurrently, improvements in patient education, electronic prescribing, and adherence-support tools have altered how montelukast is deployed in practice, with a growing emphasis on shared decision-making and individualized therapy selection. As stakeholders converge around quality, safety, and real-world performance, strategic planning must account for evolving clinical evidence, safety communications, and the broader therapeutic landscape that includes biologics, inhaled controllers, and digital health adjuncts.

Looking ahead, the intersection of established clinical utility and dynamic health system priorities requires a holistic vantage point. Commercial strategies must be informed by payer requirements, formulary placement dynamics, and channel preferences, while clinical strategies should reflect updated safety guidance and patient-centric delivery models. In short, a multidimensional understanding of montelukast's role is essential for organizations seeking to preserve therapeutic value and optimize patient outcomes within contemporary healthcare ecosystems.

Transformative developments in clinical evidence, regulatory scrutiny, and distribution dynamics that are reshaping montelukast sodium's competitive and operational landscape

The landscape surrounding montelukast sodium has been reshaped by a confluence of scientific, regulatory, and commercial shifts that are redefining stakeholder expectations and operational priorities. Advances in pharmacovigilance and large-scale real-world evidence generation have heightened scrutiny on safety signals, prompting more nuanced benefit-risk discussions with prescribers and patients. At the same time, the therapeutic ecosystem has evolved with targeted biologic therapies and advanced inhaled controllers, which are reconfiguring pathway-specific treatment choices and compelling repositioning conversations for older oral agents.

Parallel to therapeutic evolution, supply chain resilience and cost containment pressures have elevated the importance of distribution agility and channel optimization. Digital transformation in healthcare - from telemedicine-enabled prescribing to e-pharmacy growth - is changing how patients access chronic respiratory therapies and how manufacturers engage with payers and providers. Moreover, regulatory authorities worldwide are increasingly harmonizing post-market surveillance expectations while demanding greater transparency around adverse event communication, which influences label updates and promotional approaches.

Consequently, commercial models must adapt by combining rigorous safety stewardship with targeted clinical positioning that highlights appropriate patient subsets and complementary roles alongside newer therapeutics. Strategic differentiation will come from evidence-driven engagement, more granular segmentation of patient needs, and an integrated approach to channel and stakeholder management that anticipates regulatory shifts and leverages emerging distribution pathways to preserve therapeutic relevance.

How U.S. tariff adjustments through 2025 triggered strategic sourcing changes and supply chain adaptations that influence access and distribution dynamics for montelukast sodium

Policy developments in international trade and tariff regimes, including measures implemented by the United States through 2025, have exerted a meaningful influence on supply chain costs, procurement strategies, and sourcing decisions for active pharmaceutical ingredients and finished dose forms. Tariff differentials and import compliance complexities have prompted manufacturers and distributors to reassess manufacturing footprints, supplier redundancy, and customs optimization strategies. These adjustments are not merely transactional; they affect inventory management practices, lead-time buffers, and contractual terms across the supplier network.

Consequently, companies procuring raw materials or finished product for distribution within U.S. channels have placed greater emphasis on nearshoring, supplier concentration risk reduction, and alternative logistics models to mitigate tariff-driven cost exposure. In parallel, procurement teams have strengthened customs and trade compliance functions to minimize unexpected duties and to leverage tariff classifications and free trade agreements where applicable. These operational shifts have been accompanied by more conservative inventory postures in some organizations and increased collaboration with third-party logistics providers to maintain service levels while controlling landed costs.

Moreover, the ripple effects extend to channel partners and downstream stakeholders; hospital pharmacies, retail networks, and online pharmacy platforms have adjusted replenishment strategies and contract negotiations to reflect altered supplier economics. In response, manufacturers and distributors are prioritizing transparent commercial terms and flexible supply arrangements to sustain access across clinical settings. In sum, the tariff environment through 2025 has accelerated structural supply chain adaptations and elevated the strategic importance of trade-aware sourcing and distribution planning within the montelukast sodium value chain.

Deep segmentation analysis across formulation, strength, clinical application, and distribution channel to inform product positioning, manufacturing, and channel engagement strategies

A robust segmentation lens reveals differentiated clinical, commercial, and operational implications for montelukast sodium when framed by formulation, dosage strength, application, and distribution channel. When considering formulation, chewable tablet, oral granules, and conventional tablet presentations each present distinct patient adherence profiles and manufacturing considerations; chewable tablets and oral granules are particularly relevant to pediatric populations and require tailored stability and palatability strategies, whereas standard tablets emphasize cost-efficient production and established adult dosing practices. Transitioning between these formats demands attention to excipient selection, packaging design, and patient counseling to preserve therapeutic fidelity.

Dosage strength segmentation across 10mg, 4mg, and 5mg highlights dosing flexibility and the need for clear prescribing guidance. The availability of multiple strengths supports dose optimization across age groups and clinical scenarios, but it also introduces complexity in inventory management and clinician decision-making. Closely aligned with this are application-based distinctions: allergic rhinitis, asthma, and exercise-induced bronchoconstriction each present unique clinical pathways and stakeholder touchpoints. For example, allergic rhinitis often involves primary care and otolaryngology pathways with emphasis on symptomatic relief and seasonal management, while asthma care tends to involve respiratory specialists and integrated care teams with a focus on exacerbation prevention and long-term control.

Channel dynamics further nuance these considerations; hospital pharmacies, online pharmacies, and retail pharmacies each impose different fulfillment expectations, regulatory interactions, and patient service models. Hospital pharmacies often emphasize formulary alignment and inpatient continuity of care, retail pharmacies prioritize OTC-adjacent counseling and front-line dispensing efficiency, and online pharmacies drive considerations around digital patient engagement and remote adherence support. Taken together, these segmentation axes inform product development priorities, packaging and labeling strategies, and go-to-market approaches that align clinical value propositions with the operational realities of each distribution route.

Region-specific clinical, regulatory, and distribution dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape access and commercialization strategies

Regional nuances play a pivotal role in shaping clinical practice patterns, regulatory expectations, and distribution models for montelukast sodium across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, healthcare systems exhibit varied payer dynamics and a strong focus on cost-effectiveness and adherence; urban and integrated health networks emphasize formulary management and value-based contracting, while community pharmacies remain central to outpatient access. Governing authorities and professional societies influence label communication and safety advisories, which in turn influence prescriber confidence and patient acceptance.

Across Europe, the Middle East & Africa, regulatory frameworks and reimbursement pathways vary significantly, prompting differentiated approaches to evidence generation and market access engagement. Health technology assessment processes and national formulary committees often require robust safety and comparative effectiveness narratives, and regional procurement practices can favor pooled purchasing arrangements that necessitate flexible contracting. In certain markets, supply chain fragility and import dependency require contingency planning and localized distribution partnerships to maintain continuity.

In the Asia-Pacific region, rapid urbanization, expanding primary care networks, and rising digital health adoption are reshaping how chronic respiratory therapies are prescribed and dispensed. Local manufacturing capacity and regulatory pathways can differ materially between jurisdictions, and country-specific labeling or pediatric formulation preferences may drive localized product adaptations. Across all regions, evolving pharmacovigilance expectations and the increased availability of real-world evidence necessitate harmonized safety messaging and adaptive commercialization models that respect regional regulatory norms while preserving consistent clinical positioning.

How manufacturers, contract producers, distributors, and digital health partners are influencing production reliability, channel fulfillment, and clinical engagement for montelukast sodium

Competitive and collaborative dynamics among manufacturers, contract development organizations, specialty distributors, and pharmacy networks influence how montelukast sodium is produced, supplied, and positioned. Established pharmaceutical firms with legacy portfolios approach the product through integrated channel strategies, prioritizing pharmacovigilance infrastructure and long-term clinician relationships. Their investments tend to focus on label stewardship, pediatric formulation support, and broad-based educational outreach to preserve trust among prescribers and patients.

Manufacturers with contract manufacturing or outsourcing models emphasize supply reliability and cost efficiency, leveraging strategic partnerships to manage API sourcing and finished-dose production. These relationships are increasingly governed by quality agreements that incorporate traceability, change management protocols, and contingency sourcing plans to mitigate supplier disruptions. At the distribution level, specialty wholesalers and pharmacy chains vary in their expectations around lead times, rebates, and inventory commitments, which shapes commercial terms and fulfillment approaches.

Additionally, digital health providers and online pharmacy platforms are emerging as influential channel partners that extend patient engagement beyond dispensing. Their capacity to offer adherence programs, remote monitoring, and telemedicine integration creates differentiated value propositions for stakeholders seeking to optimize long-term outcomes. Cross-sector collaborations - for example, between clinical specialty societies, patient advocacy groups, and manufacturers - can amplify safety communication and education efforts, improving appropriate use and aligning stakeholders around evidence-informed practice.

Practical and prioritized recommendations for manufacturers and channel partners to enhance pharmacovigilance, supply resilience, and patient-centered commercialization for montelukast sodium

Leaders across pharmaceutical development, distribution, and clinical advocacy should adopt a multi-pronged strategy that aligns product stewardship with contemporary supply chain realities and evolving clinical expectations. First, invest in robust pharmacovigilance programs and transparent safety communication to maintain prescriber trust and to support appropriate therapeutic use. These efforts should be paired with clinician-facing education that clarifies the role of montelukast within current treatment algorithms and identifies patient cohorts most likely to derive benefit.

Second, strengthen supply chain resilience by diversifying API and finished dose suppliers, exploring regional manufacturing options, and formalizing contingency plans that address tariff-induced cost volatility and logistics disruptions. Procurement functions should collaborate closely with regulatory and quality teams to ensure continuity without compromising compliance. Third, tailor channel strategies to meet the distinct requirements of hospital pharmacies, retail networks, and online platforms; invest in packaging, patient information, and digital adherence tools that reflect the needs of pediatric and adult patient segments respectively.

Finally, pursue targeted real-world evidence initiatives and collaborative research that illuminate comparative effectiveness and long-term safety in diverse patient populations. Use these insights to inform payer dialogues and to support value propositions that resonate with formulary decision-makers and clinicians. Together, these actions create a defensible, patient-centered commercial approach that balances safety stewardship, operational resilience, and demonstrable clinical value.

Description of the evidence sources, expert engagements, and analytical techniques used to derive clinically and operationally actionable insights for montelukast sodium

The research underpinning this analysis integrated multiple evidence streams to ensure a balanced, actionable perspective. Primary inputs included interviews with clinical specialists, pharmacy directors, and supply chain leaders to capture practitioner viewpoints and operational constraints. Secondary sources comprised regulatory guidance documents, peer-reviewed clinical literature, and policy statements that informed safety, therapeutic positioning, and regional regulatory dynamics. Trade and customs publications were examined to contextualize tariff and sourcing considerations relevant to supply chain planning.

Analytical methods combined qualitative synthesis with scenario-based supply chain assessment to identify structural vulnerabilities and potential mitigants. Expert validation rounds were conducted to test key interpretations and to refine practical recommendations, ensuring that proposed actions are operationally feasible and clinically appropriate. Throughout, care was taken to triangulate findings across independent sources to minimize bias and to reflect current professional practice and policy environments.

Limitations of the approach are acknowledged; while the methodology sought breadth and depth, evolving regulatory communications and dynamic trade conditions necessitate periodic updates to maintain relevance. Nonetheless, the combination of expert interviews, regulatory analysis, and supply chain scenario planning offers a rigorous foundation for strategic decision-making in clinical, commercial, and operational domains.

Conclusive synthesis emphasizing the importance of coordinated pharmacovigilance, supply chain agility, and evidence-driven commercial strategies for montelukast sodium

In closing, montelukast sodium remains a clinically valuable therapeutic option within respiratory and allergic disease management, but its continued relevance depends on vigilant safety stewardship, adaptive supply strategies, and focused clinical positioning. The interplay of evolving pharmacovigilance expectations, shifting therapeutic alternatives, and distribution innovations requires stakeholders to act proactively across evidence generation, channel optimization, and regulatory engagement. Organizations that align clinical messaging with operational resilience and that invest in targeted real-world research will be best positioned to support clinicians and patients effectively.

Strategic emphasis on pediatric formulations and patient-centric delivery, combined with nimble procurement and trade-aware sourcing, can preserve access and adherence across care settings. Moreover, constructive collaboration among manufacturers, distributors, clinicians, and digital health partners can amplify safety communication and foster practical adherence solutions. Ultimately, a coordinated and evidence-driven approach will enable healthcare and commercial stakeholders to preserve therapeutic value and to meet patient needs in a complex and evolving environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Montelukast Sodium Market, by Formulation

  • 8.1. Chewable Tablet
  • 8.2. Oral Granules
  • 8.3. Tablet

9. Montelukast Sodium Market, by Dosage Strength

  • 9.1. 10mg
  • 9.2. 4mg
  • 9.3. 5mg

10. Montelukast Sodium Market, by Application

  • 10.1. Allergic Rhinitis
  • 10.2. Asthma
  • 10.3. Exercise-Induced Bronchoconstriction

11. Montelukast Sodium Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Montelukast Sodium Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Montelukast Sodium Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Montelukast Sodium Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Montelukast Sodium Market

16. China Montelukast Sodium Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alembic Pharmaceuticals Limited
  • 17.6. Amneal Pharmaceuticals, Inc.
  • 17.7. Apotex Inc.
  • 17.8. Aurobindo Pharma Limited
  • 17.9. Cipla Limited
  • 17.10. Dr. Reddy's Laboratories Ltd.
  • 17.11. Glenmark Pharmaceuticals Ltd.
  • 17.12. Hetero Drugs Limited
  • 17.13. Jubilant Generics Limited
  • 17.14. Lupin Limited
  • 17.15. Merck & Co., Inc.
  • 17.16. Mylan N.V.
  • 17.17. Sun Pharmaceutical Industries Ltd.
  • 17.18. Teva Pharmaceutical Industries Ltd.
  • 17.19. Torrent Pharmaceuticals Ltd.
  • 17.20. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. GLOBAL MONTELUKAST SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MONTELUKAST SODIUM MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MONTELUKAST SODIUM MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MONTELUKAST SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MONTELUKAST SODIUM MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MONTELUKAST SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY CHEWABLE TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY CHEWABLE TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY CHEWABLE TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ORAL GRANULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ORAL GRANULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ORAL GRANULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY 10MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY 10MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY 10MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY 4MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY 4MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY 4MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY 5MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY 5MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY 5MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ALLERGIC RHINITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ALLERGIC RHINITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ASTHMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ASTHMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ASTHMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY EXERCISE-INDUCED BRONCHOCONSTRICTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY EXERCISE-INDUCED BRONCHOCONSTRICTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY EXERCISE-INDUCED BRONCHOCONSTRICTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS MONTELUKAST SODIUM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA MONTELUKAST SODIUM MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 70. MIDDLE EAST MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 75. AFRICA MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 86. ASEAN MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GCC MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GCC MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 91. GCC MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 92. GCC MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. GCC MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPEAN UNION MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 101. BRICS MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. G7 MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. G7 MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. G7 MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 107. G7 MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 108. G7 MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. NATO MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NATO MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 111. NATO MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 112. NATO MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. NATO MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MONTELUKAST SODIUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES MONTELUKAST SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 117. UNITED STATES MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA MONTELUKAST SODIUM MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA MONTELUKAST SODIUM MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 122. CHINA MONTELUKAST SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA MONTELUKAST SODIUM MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA MONTELUKAST SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)